A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou · Large multi-institution collaboration (~120 authors); first authors Gordon, Jang, Bouhaddou; senior author Nevan J. Krogan (QCRG/QBI COVID-19 Research Group).
Summary
The authors expressed 26 of the 29 SARS-CoV-2 proteins in human cells and used affinity-purification mass spectrometry to map 332 high-confidence virus-human protein-protein interactions. They then identified 69 existing drugs and compounds that target the human proteins in this interactome and tested several for antiviral activity. Two pharmacological classes (mRNA translation inhibitors and Sigma1/Sigma2 receptor regulators) showed antiviral effects, providing candidate therapeutics for repurposing.
Key findings
- Mapped 332 high-confidence SARS-CoV-2-human protein-protein interactions across 26 viral proteins.
- Linked the host interactors to 69 existing FDA-approved drugs, clinical-trial compounds, and preclinical molecules.
- Antiviral testing implicated translation inhibitors and Sigma receptor ligands as promising therapeutic candidates.
Subjects & keywords
Cite this paper
David E. Gordon, Gwendolyn M. Jang, & Mehdi Bouhaddou [Large multi-institution collaboration (~120 authors); first authors Gordon, Jang, Bouhaddou; senior author Nevan J. Krogan (QCRG/QBI COVID-19 Research Group).] (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9
@article{gordon2020sarscov2,
author = {David E. Gordon and Gwendolyn M. Jang and Mehdi Bouhaddou and {Large multi-institution collaboration (~120 authors); first authors Gordon, Jang, Bouhaddou; senior author Nevan J. Krogan (QCRG/QBI COVID-19 Research Group).}},
title = {A SARS-CoV-2 protein interaction map reveals targets for drug repurposing},
journal = {Nature},
year = {2020},
doi = {10.1038/s41586-020-2286-9},
url = {https://doi.org/10.1038/s41586-020-2286-9}
}